Article Type
Case Report
Published
This case report examines silymarin treatment prescribed to a patient with overweight and non-alcoholic fatty liver disease, with an attempt to manage the increased liver enzyme activity levels.
Current clinical use of silymarin in the treatment of toxic liver diseases: a case series
Toxic liver diseases consist of different kinds of liver injuries of different aetiologies, caused by endogenous factors such as dysmetabolic conditions – diabetes, dyslipidaemia, hypertension or obesity – or exogenous triggers such as drugs, alcohol or chemicals. Over the long term, such induced liver damage can progress to chronic liver disease. Unfortunately, limited treatment options are available. This case series shows clinical examples of patients diagnosed with liver damage due to comorbid conditions and multiple risk factors and successfully treated with silymarin to mitigate the altered liver functionality.
Article Type
Case Report
Published
This case report discusses personalized management of a patient with metabolic-associated fatty liver disease with advanced fibrosis and severe steatosis. The article examines impact of silymarin use, concomitant treatment with diet, exercise, insulin sensitizers and antifibrotic agents.
Article Type
Case Report
Published
This case report focuses on a patient planning surgery due to lumbar stenosis who was recommended for silymarin treatment, as increased liver enzyme levels were incidentally
found during examination.
Article Type
Case Report
Published
This case report discusses daily treatment with silymarin and highlights moderate efficacy and a good safety profile in the management of non-alcoholic steatohepatitis (NASH) and liver function with no side-effects, supporting silymarin as a promising supplemental intervention that can normalize liver activity in non-alcoholic fatty liver disease and NASH.
Article Type
Case Report
Published
This case report discusses a patient with tuberculosis who experienced drug-induced liver injury, and the initiation of treatment with silymarin resulted in a significant hepatoprotective effects as shown by decreased liver enzyme activity.
Article Type
Case Report
Published
This report discusses silymarin in a patient with diabetes and grade II non-alcoholic steatohepatitis, confirming significant hepatoprotective effects as shown by the reduction of liver enzyme activities.
